ASX:RAD

3 stories mentioning ASX:RADUpdated 38d ago

Every FINWIRES story that references ASX:RAD, newest first.

Radiopharm Theranostics Reports Decline in Cash at End of March

Radiopharm Theranostics (ASX:RAD) said it closed the March quarter with a cash position of AU$19.2 million, down from AU$34.5 million at the end of the previous quarter, according to a Thursday filing with the Australian bourse.The company reported net cash outflows from operating activities of AU$14.9 million for the quarter, with direct research and development expenses and staff costs representing 95% of the total.Radiopharm Theranostics has completed enrolment in a phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases, and has also received a positive recommendation from the Data and Safety Monitoring Committee to advance its RAD 202 radiopharmaceutical therapy candidate to the next dose level, per the filing.

ASX:RAD

Asia59d ago

Radiopharm Says In-Human Trial Results Show 'Meaningful' Tumor Uptake, Favorable Safety Profile for Radiotherapeutic Candidate

Radiopharm Theranostics (ASX:RAD) said the first in-human findings from the ongoing Phase 0/1 HEAT trial evaluating its radiotherapeutic candidate, lutetium-177-RAD202, showed "meaningful" tumor uptake and a favorable safety profile at the lowest dose level of 30 millicurie (mCi), according to a Monday Australian bourse filing.Organ-level absorbed radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation, while no dose-limiting toxicities or treatment discontinuations due to adverse events were observed, per the filing.The radiotherapeutic candidate was generally well tolerated in the first three treated patients, with predominantly grade one to two treatment-emergent adverse events, the filing added.Radiopharm Theranostics' shares rose past 2% in recent trading on Monday.

ASX:RAD

Asia63d ago

Radiopharm Theranostics Completes Dosing of Final Patient in Phase 2B Imaging Trial in Recurrent Brain Metastases from Solid Tumors

Radiopharm Theranostics (ASX:RAD) completed the dosing of the final patient in the US phase 2b imaging trial evaluating the diagnostic performance of fluorine-18-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors of different origins, according to a Thursday Australian bourse filing.The primary objective of the study is concordance between fluorine-18-RAD101 positive lesions and those seen in conventional imaging, magnetic resonance imaging with gadolinium, in participants with suspected recurrent brain metastases.RAD 101 is a novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis and is overexpressed in many solid tumors.

ASX:RAD

Track with the FINWIRES app suite

FolioX

Track ASX:RAD in your portfolio

WheelAI

Analyze ASX:RAD options with the wheel strategy

StockInsider

See market sentiment on ASX:RAD